Argenx Se (ARGXN) Q3 2026 Earnings Report

The call was strongly positive, supported by 54% year-over-year product sales growth, continued momentum in both MG and CIDP, positive ALKIVIA and FB102 data, a broadening pipeline and expectations for up to five potential launches in 2027. The main challenges were the dermatomyositis confirmatory-trial requirement, the Sjögren's futility outcome, elevated planned operating expenses and limited formal revenue guidance, but these issues were outweighed by the company's commercial performance, financial strength and pipeline progress.

Management expects 10 molecules in clinical development by the end of this year, combined R&D and SG&A expenses of approximately $4 billion for 2026, a 45% increase year-over-year from 2025, and for 2027 said, “please do not assume another 45% increase,” with investors to “Think of about half of that 45% if you need something for your models now”; more guidance is expected at JPMorgan. The company expects 5 potential launches across its portfolio in 2027, or “up to 5 launches in a single year in the U.S.,” including a pediatric MG PDUFA date of February 2027, a VYVGART Hytrulo auto-injector in the second half of 2027, an IMNM sBLA by year-end, and potentially MMN following the EMPASSION readout in December and a priority-review application if data are positive. Management expects about 2 quarters after approval to get payer policies in place for IMNM, expects 10 clinical-stage molecules by the end of this year, is “well on track” for 10 labeled indications and 5 molecules in Phase III development by the end of the decade, and reiterated Vision 2030 targets of 50,000 patients by the end of the decade.